Your browser is no longer supported. Please, upgrade your browser.
VNDA Vanda Pharmaceuticals Inc. daily Stock Chart
VNDA [NASD]
Vanda Pharmaceuticals Inc.
Index- P/E126.23 EPS (ttm)0.24 Insider Own3.20% Shs Outstand52.54M Perf Week6.23%
Market Cap1.59B Forward P/E47.36 EPS next Y0.64 Insider Trans-1.67% Shs Float51.20M Perf Month14.98%
Income13.00M PEG- EPS next Q0.01 Inst Own- Short Float8.70% Perf Quarter41.38%
Sales184.40M P/S8.60 EPS this Y16.00% Inst Trans0.09% Short Ratio6.30 Perf Half Y48.26%
Book/sh4.99 P/B6.05 EPS next Y128.32% ROA4.60% Target Price42.50 Perf Year112.46%
Cash/sh4.58 P/C6.59 EPS next 5Y- ROE5.90% 52W Range13.88 - 33.44 Perf YTD15.46%
Dividend- P/FCF89.56 EPS past 5Y19.30% ROI-13.00% 52W High-9.78% Beta0.76
Dividend %- Quick Ratio6.00 Sales past 5Y38.20% Gross Margin89.40% 52W Low117.44% ATR1.36
Employees273 Current Ratio6.00 Sales Q/Q18.90% Oper. Margin5.70% RSI (14)66.23 Volatility3.58% 5.21%
OptionableYes Debt/Eq0.00 EPS Q/Q229.30% Profit Margin7.10% Rel Volume1.01 Prev Close29.29
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout0.00% Avg Volume707.02K Price30.17
Recom1.70 SMA2013.21% SMA5019.14% SMA20046.47% Volume712,094 Change3.00%
Dec-11-18Downgrade Oppenheimer Outperform → Perform
Dec-04-18Upgrade Cantor Fitzgerald Neutral → Overweight
Dec-04-18Reiterated Jefferies Buy $30 → $40
Nov-08-18Resumed Jefferies Buy
Sep-21-18Resumed Oppenheimer Outperform
May-23-18Initiated Citigroup Buy $26
Jan-19-18Initiated Seaport Global Securities Buy $20
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
Apr-12-17Initiated Oppenheimer Outperform $21
Nov-09-16Initiated Aegis Capital Buy $24
Oct-06-16Resumed Jefferies Buy
Jan-09-15Initiated Canaccord Genuity Buy $22
Mar-10-10Initiated Hapoalim Outperform $23
Feb-17-10Reiterated Jefferies & Co Buy $22 → $20
Dec-09-09Initiated Jefferies & Co Buy $22
Jul-29-08Downgrade JP Morgan Overweight → Neutral
Jul-29-08Downgrade Banc of America Sec Buy → Neutral
Jul-28-08Downgrade Caris & Company Buy → Above Average $22 → $3
Jan-16-19 06:59AM  5 Stocks With Recent Price Strength Despite Volatile Market Zacks
Jan-14-19 09:46AM  ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study Zacks
Jan-10-19 10:00AM  Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect Zacks
Jan-09-19 09:50AM  Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan Zacks
Jan-08-19 05:20PM  Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results Zacks
Jan-07-19 10:09AM  Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed Zacks
Jan-04-19 12:02PM  Bull or Bear: Your Investment Strategy for 2019 Zacks +6.69%
10:01AM  Vertex Joins Forces With Arbor to Build Gene-Editing Therapies Zacks
Dec-31-18 08:10AM  Emergent (EBS) Files Application for Emergency Use of NuThrax Zacks
07:51AM  4 of the Fastest Growing Biotech Stocks in 2019 Motley Fool
Dec-24-18 08:39AM  Ring in 2019 With These 7 Solid Growth Stocks in Your Kitty Zacks
Dec-21-18 03:57PM  These 2 Biotech Stocks Snub The Stock Market Correction Investor's Business Daily
Dec-20-18 07:00AM  FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application for Review in the Treatment of Jet Lag Disorder PR Newswire
Dec-16-18 09:45AM  Vanda Pharmaceuticals Inc. (VNDA): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-14-18 07:11AM  The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance Zacks
06:59AM  How Does Investing In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Impact The Volatility Of Your Portfolio? Simply Wall St.
06:33AM  The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance Zacks
Dec-13-18 09:21AM  The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance Zacks
Dec-12-18 09:02AM  4 Stocks That Had Massive Earnings Surprises in 2018 Zacks
Dec-10-18 07:00AM  Vanda Announces Positive Pivotal Study Results for HETLIOZ® (tasimelteon) in Patients with Smith-Magenis Syndrome PR Newswire
Dec-05-18 09:49AM  Inovio (INO) to Receive Milestone Payment From AstraZeneca Zacks
Dec-04-18 04:34PM  Amgen's BiTE Immunotherapies Show Promise in Early Studies Zacks -8.04%
09:30AM  Company News For Dec 4, 2018 Zacks
07:59AM  The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO Benzinga
Dec-03-18 09:41AM  FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate Zacks +25.68%
06:00AM  Vanda Announces Positive Phase II Study Results for Tradipitant in Patients with Gastroparesis PR Newswire
Nov-29-18 08:05AM  Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines Zacks
Nov-28-18 08:18AM  5 Stocks With Recent Price Strength to Strengthen Portfolio Zacks
Nov-20-18 03:52PM  Edited Transcript of VNDA earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-16-18 10:20AM  Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy? Zacks
Nov-08-18 05:35PM  Vanda Pharmaceuticals Announces Participation at November 2018 Investor Conferences PR Newswire +14.72%
04:16PM  This Biotech Stock Briefly Edged Into Buy Zone On Earnings Crush Investor's Business Daily
Nov-07-18 06:25PM  Vanda Pharmaceuticals (VNDA) Surpasses Q3 Earnings and Revenue Estimates Zacks
05:22PM  Vanda: 3Q Earnings Snapshot Associated Press
04:01PM  Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results PR Newswire
Nov-02-18 02:06PM  The FDA is cracking down on a local drugmaker. The company isn't completely sure why. American City Business Journals
Nov-01-18 01:30PM  A Look At The Intrinsic Value Of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Simply Wall St. +6.91%
09:40AM  Vanda Receives FDA Letter Regarding Corporate Webpage PR Newswire
Oct-31-18 10:32AM  Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Oct-24-18 07:30AM  Consolidated Research: 2018 Summary Expectations for Airgain, Vanda Pharmaceuticals, Westlake Chemical, TransEnterix, Versum Materials, and Triumph Group Fundamental Analysis, Key Performance Indications GlobeNewswire -7.54%
Oct-23-18 04:41PM  This IBD Stock Of The Day Is Heading For Fourth Quarter Of Profitability Investor's Business Daily
Oct-22-18 04:30PM  Vanda Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 7, 2018 PR Newswire
Sep-27-18 08:31AM  Vanda Pharmaceuticals (VNDA) Catches Eye: Stock Jumps 8.7% Zacks
Sep-26-18 04:30PM  Vanda Pharmaceuticals Announces Participation at Oppenheimer and Cantor Fitzgerald Fall 2018 Investor Conferences PR Newswire +8.72%
04:19PM  Here's Why The Stock Market Sold Off After The Fed Meeting Investor's Business Daily
02:41PM  Why Vanda Pharmaceuticals' Shares Are Soaring 10% Today Motley Fool
08:25AM  The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial Benzinga
Sep-25-18 06:26PM  Rollins Set to Join S&P 500; Inogen to Join S&P MidCap 400; Vanda Pharmaceuticals and Garrett Motion to Join S&P SmallCap 600 PR Newswire
Sep-20-18 05:05PM  Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book PR Newswire
Sep-17-18 12:00PM  Vanda Pharmaceuticals Inc (NASDAQ:VNDA): Commentary On Fundamentals Simply Wall St.
Sep-12-18 07:00PM  HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment in Next Morning Performance PR Newswire
Sep-04-18 04:35PM  Vanda Pharmaceuticals Announces Participation at September 2018 Investor Conferences PR Newswire
Aug-14-18 04:45PM  Vanda Wins Denial of Petition For Rehearing on Fanapt® PR Newswire
Aug-13-18 04:01PM  Vanda Pharmaceuticals Announces the Appointment of General Counsel PR Newswire
09:40AM  Edited Transcript of VNDA earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-06-18 09:11AM  Zacks.com highlights: G-III Apparel Group, Rocky Brands, Vail Resorts, Vanda Pharmaceuticals and IntriCon Zacks
Aug-03-18 05:38PM  Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2 Zacks
09:51AM  5 Low-Beta Stocks to Take Refuge in a Volatile Market Zacks
Aug-02-18 11:47AM  Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally Zacks +5.08%
08:20AM  Zacks.com featured highlights include: Vanda, Turtle Beach, PCM and Turning Point Zacks
Aug-01-18 05:50PM  Vanda Pharmaceuticals (VNDA) Beats Q2 Earnings Estimates Zacks
04:42PM  Vanda: 2Q Earnings Snapshot Associated Press
04:01PM  Vanda Pharmaceuticals Reports Second Quarter 2018 Financial Results PR Newswire
10:09AM  Endocyte (ECYT) Posts Narrower-Than-Expected Loss in Q2 Zacks
Jul-26-18 09:59AM  The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group Zacks
Jul-25-18 12:24PM  AbbVie Secures FDA Approval for Endometriosis Drug Elagolix Zacks
07:58AM  Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions Zacks
Jul-24-18 12:00PM  AstraZeneca Sells Atacand's European Rights to Cheplapharm Zacks
11:57AM  Allergan's Depression Candidate Gets Fast Track Designation Zacks
Jul-20-18 11:35AM  Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label Zacks
Jul-17-18 04:30PM  Vanda Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 1, 2018 PR Newswire
Jul-16-18 10:45AM  J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay Zacks
Jul-10-18 07:35AM  Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks ACCESSWIRE
Jun-27-18 07:50AM  Detailed Research: Economic Perspectives on Comerica, Vanda Pharmaceuticals, Acadia Healthcare, The Charles Schwab, Ares Capital, and EQT What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-08-18 07:00AM  TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
Jun-01-18 12:00PM  Vanda Pharmaceuticals Announces Participation at June 2018 Investor Conferences PR Newswire
May-24-18 03:00AM  Stocks Generating Improved Relative Strength: Vanda Pharmaceuticals Investor's Business Daily
May-23-18 08:00AM  HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel PR Newswire
May-16-18 11:52AM  Edited Transcript of VNDA earnings conference call or presentation 2-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 08:00AM  Investor Expectations to Drive Momentum within Plains Group Holdings, EnteroMedics, Vanda Pharmaceuticals, Cinemark, EPR Properties, and The Estee Lauder Companies Discovering Underlying Factors of Influence GlobeNewswire
May-07-18 09:00AM  Vanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference PR Newswire
May-02-18 05:43PM  Vanda: 1Q Earnings Snapshot Associated Press
04:01PM  Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results PR Newswire
Apr-30-18 08:50AM  AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store? Zacks
Apr-27-18 07:44AM  Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals Zacks
Apr-26-18 12:35PM  4 Top Efficient Stocks to Buy for Stellar Returns InvestorPlace
10:20AM  4 Top Efficient Stocks to Buy for Stellar Returns Zacks
Apr-24-18 08:06AM  Vanda Pharmaceuticals Inc. (VNDA) Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-18-18 04:30PM  Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018 PR Newswire
Apr-13-18 12:00PM  Vanda Wins Appeal Case on Fanapt® PR Newswire
Apr-09-18 04:01PM  Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis PR Newswire -5.52%
Mar-16-18 08:30AM  Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Investors Are Paying Above The Intrinsic Value Simply Wall St. -5.28%
Mar-15-18 07:46PM  Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock PR Newswire -11.04%
Mar-14-18 04:01PM  Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock PR Newswire
Mar-06-18 04:30PM  Vanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences PR Newswire
Mar-05-18 09:24PM  A drug for jet lag? A D.C. biotech says it just got a lot closer. American City Business Journals
07:00AM  HETLIOZ® (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study PR Newswire
Feb-26-18 07:10AM  Wired News Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem Meetings ACCESSWIRE
Feb-16-18 03:08AM  Edited Transcript of VNDA earnings conference call or presentation 14-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-14-18 04:01PM  Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results PR Newswire
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Birznieks GuntherSVP, Business DevelopmentJan 03Sale26.091,61942,232133,780Jan 04 04:34 PM
Kelly James PatrickEVP & Chief Financial OfficerJan 03Sale26.091,61942,232193,473Jan 04 04:33 PM
Polymeropoulos Mihael HristosPresident and CEOJan 03Sale26.044,447115,8041,163,636Jan 04 04:31 PM
Reverberi Gian PieroSVP & Chief Commercial OfficerJan 02Sale26.591,13030,042138,870Jan 04 04:37 PM
Birznieks GuntherSVP, Business DevelopmentJan 02Sale26.474,442117,578135,399Jan 04 04:34 PM
Kelly James PatrickEVP & Chief Financial OfficerJan 02Sale26.474,442117,579195,092Jan 04 04:33 PM
Polymeropoulos Mihael HristosPresident and CEOJan 02Sale26.5010,789285,8581,168,083Jan 04 04:31 PM
Watkins ThomasDirectorMay 03Option Exercise4.9815,00074,70020,000May 04 04:06 PM
DUGAN RICHARD WDirectorMar 19Option Exercise4.9815,00074,70025,770Mar 20 05:02 PM
Polymeropoulos Mihael HristosPresident and CEOMar 01Sale18.7260,9661,141,0031,182,872Mar 02 05:36 PM
Kelly James PatrickEVP & Chief Financial OfficerMar 01Sale18.728,532159,712199,534Mar 02 05:34 PM
Birznieks GuntherSVP, Business DevelopmentMar 01Sale18.728,525159,605139,841Mar 02 05:32 PM
Gulino Richard L.SVP, General Counsel & Sec.Mar 01Sale18.713,66068,473115,073Mar 02 05:33 PM